AUPH icon

Aurinia Pharmaceuticals

Positive
Neutral
Negative
Sentiment 3-Months
Positive
Neutral 55.6%
Negative

Neutral
Business Wire
yesterday
Aurinia Announces Upcoming Presentations of New Data on LUPKYNIS® at American College of Rheumatology Convergence and American Society of Nephrology Kidney Week 2025
ROCKVILLE, Md. & EDMONTON, Alberta--(BUSINESS WIRE)--Aurinia Announces Upcoming Presentations of New Data on LUPKYNIS® at ACR Convergence and ASN Kidney Week 2025.
Aurinia Announces Upcoming Presentations of New Data on LUPKYNIS® at American College of Rheumatology Convergence and American Society of Nephrology Kidney Week 2025
Neutral
Business Wire
16 days ago
Aurinia Responds to Now Retracted LinkedIn Post
ROCKVILLE, Md. & EDMONTON, Alberta--(BUSINESS WIRE)--Aurinia Responds to Now Retracted LinkedIn Post.
Aurinia Responds to Now Retracted LinkedIn Post
Negative
Seeking Alpha
2 months ago
Aurinia Pharma: The Easiest Money May Have Been Made (Rating Downgrade)
Aurinia Pharmaceuticals Inc. reported total revenues of $70M in Q2 '25, aided by record Lupkynis net product sales of $66.6M. AUPH management continues to execute well, maintaining positive cash flow, but faces the risk of having only one revenue-generating drug. AUR200 doesn't appear to be worthless; instead, it could have the potential to compete with other compounds in the same class, although it isn't first-in-class.
Aurinia Pharma: The Easiest Money May Have Been Made (Rating Downgrade)
Positive
Zacks Investment Research
2 months ago
Aurinia (AUPH) Upgraded to Buy: Here's What You Should Know
Aurinia (AUPH) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Aurinia (AUPH) Upgraded to Buy: Here's What You Should Know
Positive
The Motley Fool
2 months ago
Aurinia (AUPH) Q2 Revenue Jumps 22%
Aurinia Pharmaceuticals (AUPH 2.15%), a biopharmaceutical company focused on therapies for autoimmune diseases, released its second-quarter 2025 earnings on July 31, 2025. The headline news: revenue (GAAP) came in at $70.0 million, which exceeded analyst expectations of $63.8 million by 9.7% (GAAP).
Aurinia (AUPH) Q2 Revenue Jumps 22%
Neutral
Seeking Alpha
2 months ago
Aurinia Pharmaceuticals Inc. (AUPH) Q2 2025 Earnings Call Transcript
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH ) Q2 2025 Earnings Conference Call July 31, 2025 8:30 AM ET Company Participants Gregory F. Keenan - Chief Medical Officer Joseph M.
Aurinia Pharmaceuticals Inc. (AUPH) Q2 2025 Earnings Call Transcript
Negative
Zacks Investment Research
2 months ago
Aurinia Pharmaceuticals (AUPH) Q2 Earnings Miss Estimates
Aurinia Pharmaceuticals (AUPH) came out with quarterly earnings of $0.16 per share, missing the Zacks Consensus Estimate of $0.17 per share. This compares to earnings of $0.02 per share a year ago.
Aurinia Pharmaceuticals (AUPH) Q2 Earnings Miss Estimates
Neutral
Business Wire
2 months ago
Aurinia Pharmaceuticals Reports Financial Results for the Three and Six Months Ended June 30, 2025
ROCKVILLE, Md.& EDMONTON, Alberta--(BUSINESS WIRE)--Aurinia Pharmaceuticals Reports Financial Results for the Three and Six Months Ended June 30, 2025.
Aurinia Pharmaceuticals Reports Financial Results for the Three and Six Months Ended June 30, 2025
Neutral
Business Wire
2 months ago
Aurinia Pharmaceuticals to Release Second Quarter 2025 Financial and Operational Results on July 31, 2025
ROCKVILLE, Md. & EDMONTON, Alberta--(BUSINESS WIRE)--Aurinia Pharmaceuticals to Release Second Quarter 2025 Financial and Operational Results on July 31, 2025.
Aurinia Pharmaceuticals to Release Second Quarter 2025 Financial and Operational Results on July 31, 2025
Positive
Seeking Alpha
3 months ago
The Play On Aurinia Pharmaceuticals: Rising Cash Flow Provides Opportunity
I revisit biopharma name Aurinia Pharmaceuticals Inc. for the first time in 2025 after the company reported solid Q1 results in May. The quarter saw Lupkynis net product revenues up 25% year-over-year to $60 million and management reaffirm FY2025 guidance. The company has a strong balance sheet, a free cash flow turnaround, and projected profit growth to $0.59/share in FY2025 to support a positive investment outlook.
The Play On Aurinia Pharmaceuticals: Rising Cash Flow Provides Opportunity